LT3310816T - Cys80 konjuguoti imunoglobulinai - Google Patents
Cys80 konjuguoti imunoglobulinaiInfo
- Publication number
- LT3310816T LT3310816T LTEP16736952.9T LT16736952T LT3310816T LT 3310816 T LT3310816 T LT 3310816T LT 16736952 T LT16736952 T LT 16736952T LT 3310816 T LT3310816 T LT 3310816T
- Authority
- LT
- Lithuania
- Prior art keywords
- conjugated immunoglobulins
- cys80 conjugated
- cys80
- immunoglobulins
- conjugated
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182020P | 2015-06-19 | 2015-06-19 | |
PCT/US2016/038041 WO2016205618A1 (en) | 2015-06-19 | 2016-06-17 | Cys80 conjugated immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3310816T true LT3310816T (lt) | 2020-11-25 |
Family
ID=56404289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP16736952.9T LT3310816T (lt) | 2015-06-19 | 2016-06-17 | Cys80 konjuguoti imunoglobulinai |
Country Status (33)
Country | Link |
---|---|
US (3) | US10273310B2 (lt) |
EP (2) | EP3795591B1 (lt) |
JP (2) | JP6823606B2 (lt) |
KR (1) | KR20180021807A (lt) |
CN (1) | CN107949575B (lt) |
AU (1) | AU2016280190B9 (lt) |
BR (1) | BR112017027252A2 (lt) |
CA (1) | CA2989637C (lt) |
CL (1) | CL2017003273A1 (lt) |
CO (1) | CO2017013303A2 (lt) |
CY (1) | CY1123481T1 (lt) |
DK (2) | DK3310816T3 (lt) |
ES (2) | ES2967613T3 (lt) |
HK (1) | HK1252625A1 (lt) |
HR (1) | HRP20201489T1 (lt) |
HU (2) | HUE064407T2 (lt) |
IL (1) | IL256263B (lt) |
LT (1) | LT3310816T (lt) |
MA (1) | MA44207B1 (lt) |
MD (1) | MD3310816T2 (lt) |
MX (1) | MX2017016674A (lt) |
MY (1) | MY189024A (lt) |
PE (1) | PE20180498A1 (lt) |
PH (1) | PH12017502352A1 (lt) |
PL (1) | PL3310816T3 (lt) |
PT (1) | PT3310816T (lt) |
RS (1) | RS60943B1 (lt) |
RU (1) | RU2756101C2 (lt) |
SG (1) | SG10201913935RA (lt) |
SI (1) | SI3310816T1 (lt) |
UA (1) | UA124830C2 (lt) |
WO (1) | WO2016205618A1 (lt) |
ZA (2) | ZA201708619B (lt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022008756A2 (pt) | 2019-11-07 | 2022-07-26 | Eisai R&D Man Co Ltd | Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso |
US20230137966A1 (en) * | 2020-02-12 | 2023-05-04 | Eli Lilly And Company | Crystallization of Antibodies or Antigen-Binding Fragments |
IL298053A (en) | 2020-06-05 | 2023-01-01 | Eisai R&D Man Co Ltd | Antibody-drug conjugates against bcma and methods of use |
CN112694521B (zh) * | 2020-12-02 | 2023-01-17 | 杭州百凌生物科技有限公司 | 一种人工多肽lh、其抗体及在病理检测中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL193352B1 (pl) * | 1998-04-28 | 2007-02-28 | Applied Research Systems | Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna |
US6904369B1 (en) * | 2000-06-29 | 2005-06-07 | The Trustees Of Columbia University In The City Of New York | Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor |
US7402409B2 (en) | 2003-01-23 | 2008-07-22 | Epitomics, Inc. | Cell fusion method |
CA2533830A1 (en) * | 2003-08-07 | 2005-02-24 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
WO2006017759A2 (en) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
PT2164868E (pt) * | 2007-05-04 | 2015-08-04 | Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa | Domínios variáveis de anticorpos de coelho manipulados e suas utilizações |
NZ601583A (en) * | 2007-05-21 | 2013-08-30 | Bristol Myers Squibb Co | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
CA2711736A1 (en) * | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
WO2010118203A2 (en) | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
BR112012030311A2 (pt) * | 2010-06-08 | 2017-01-24 | Genentech Inc | anticorpo |
JP5913307B2 (ja) * | 2010-07-12 | 2016-04-27 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 多機能性抗体複合体 |
CN102008732B (zh) * | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | 一种叶酸偶联抗体药物及其制备方法与应用 |
WO2014031476A1 (en) * | 2012-08-21 | 2014-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
KR20190121874A (ko) | 2012-08-29 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
-
2016
- 2016-06-17 JP JP2017565751A patent/JP6823606B2/ja active Active
- 2016-06-17 EP EP20192124.4A patent/EP3795591B1/en active Active
- 2016-06-17 CN CN201680035726.6A patent/CN107949575B/zh active Active
- 2016-06-17 UA UAA201713079A patent/UA124830C2/uk unknown
- 2016-06-17 PE PE2017002753A patent/PE20180498A1/es unknown
- 2016-06-17 PL PL16736952T patent/PL3310816T3/pl unknown
- 2016-06-17 US US15/185,879 patent/US10273310B2/en active Active
- 2016-06-17 BR BR112017027252-0A patent/BR112017027252A2/pt active Search and Examination
- 2016-06-17 MX MX2017016674A patent/MX2017016674A/es unknown
- 2016-06-17 LT LTEP16736952.9T patent/LT3310816T/lt unknown
- 2016-06-17 SI SI201630933T patent/SI3310816T1/sl unknown
- 2016-06-17 CA CA2989637A patent/CA2989637C/en active Active
- 2016-06-17 RS RS20201246A patent/RS60943B1/sr unknown
- 2016-06-17 MD MDE20180417T patent/MD3310816T2/ro unknown
- 2016-06-17 WO PCT/US2016/038041 patent/WO2016205618A1/en active Application Filing
- 2016-06-17 SG SG10201913935RA patent/SG10201913935RA/en unknown
- 2016-06-17 DK DK16736952.9T patent/DK3310816T3/da active
- 2016-06-17 HU HUE20192124A patent/HUE064407T2/hu unknown
- 2016-06-17 MA MA44207A patent/MA44207B1/fr unknown
- 2016-06-17 HU HUE16736952A patent/HUE051315T2/hu unknown
- 2016-06-17 PT PT167369529T patent/PT3310816T/pt unknown
- 2016-06-17 ES ES20192124T patent/ES2967613T3/es active Active
- 2016-06-17 ES ES16736952T patent/ES2829251T3/es active Active
- 2016-06-17 DK DK20192124.4T patent/DK3795591T3/da active
- 2016-06-17 RU RU2017146220A patent/RU2756101C2/ru active
- 2016-06-17 EP EP16736952.9A patent/EP3310816B1/en active Active
- 2016-06-17 AU AU2016280190A patent/AU2016280190B9/en active Active
- 2016-06-17 MY MYPI2017001842A patent/MY189024A/en unknown
- 2016-06-17 KR KR1020187001769A patent/KR20180021807A/ko not_active Application Discontinuation
-
2017
- 2017-12-12 IL IL256263A patent/IL256263B/en unknown
- 2017-12-18 PH PH12017502352A patent/PH12017502352A1/en unknown
- 2017-12-18 ZA ZA2017/08619A patent/ZA201708619B/en unknown
- 2017-12-19 CL CL2017003273A patent/CL2017003273A1/es unknown
- 2017-12-22 CO CONC2017/0013303A patent/CO2017013303A2/es unknown
-
2018
- 2018-09-17 HK HK18111926.6A patent/HK1252625A1/zh unknown
-
2019
- 2019-03-14 US US16/353,326 patent/US11129904B2/en active Active
-
2020
- 2020-07-28 JP JP2020127204A patent/JP7042876B2/ja active Active
- 2020-09-18 HR HRP20201489TT patent/HRP20201489T1/hr unknown
- 2020-10-20 CY CY20201100992T patent/CY1123481T1/el unknown
-
2021
- 2021-03-29 ZA ZA2021/02093A patent/ZA202102093B/en unknown
- 2021-09-02 US US17/464,815 patent/US20230001004A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285516B (en) | Amatoxin antibody conjugates | |
AU201616677S (en) | Cylindres | |
GB201513607D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
ZA202102093B (en) | Cys80 conjugated immunoglobulins | |
HK1257229A1 (zh) | Cck2r-藥物偶聯物 | |
PL3270711T3 (pl) | Koniugaty cukier-dipeptyd | |
SG10201506686WA (en) | Conjugates | |
AU2016376V (en) | NinbellaPurple Alyogyne huegelii | |
AU2016360V (en) | JCU7 Desmanthus leptophyllus | |
AU2016359V (en) | JCU6 Desmanthus bicornutus | |
AU2016361V (en) | JCU8 Desmanthus virgatus | |
AU2016362V (en) | JCU9 Desmanthus pernambucanus | |
AU201616673S (en) | tallboy | |
AU2016303V (en) | Desse1601 Desmanthus virgatus | |
AP2016001138S (en) | Chisa kooka | |
AU2016204V (en) | LEP01 Lepidosperma gladiatum | |
AU201612879S (en) | Sprayer | |
AU2016185V (en) | LowGuichGL Guichenotia macrantha | |
AU2016186V (en) | LowadenGL Adenanthos sericeus | |
AU2016187V (en) | DamprostGL Westringia dampieri | |
AU2016162V (en) | Kingscawite Scaevola aemula | |
GB201600127D0 (en) | Concept ABCD13 | |
GB201600128D0 (en) | Concept ABCD14 | |
GB201518839D0 (en) | Conjugates | |
GB201513605D0 (en) | Pyrrolobenzodiazepine-antibody conjugates |